![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RPL21 |
Gene summary for RPL21 |
![]() |
Gene information | Species | Human | Gene symbol | RPL21 | Gene ID | 6144 |
Gene name | ribosomal protein L21 | |
Gene Alias | HYPT12 | |
Cytomap | 13q12.2 | |
Gene Type | protein-coding | GO ID | GO:0002181 | UniProtAcc | P46778 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6144 | RPL21 | GSM4909282 | Human | Breast | IDC | 1.80e-32 | -2.56e-01 | -0.0288 |
6144 | RPL21 | GSM4909285 | Human | Breast | IDC | 1.46e-08 | 1.64e-01 | 0.21 |
6144 | RPL21 | GSM4909286 | Human | Breast | IDC | 5.12e-21 | 2.10e-01 | 0.1081 |
6144 | RPL21 | GSM4909287 | Human | Breast | IDC | 1.58e-20 | -3.58e-01 | 0.2057 |
6144 | RPL21 | GSM4909290 | Human | Breast | IDC | 1.84e-13 | -2.56e-01 | 0.2096 |
6144 | RPL21 | GSM4909292 | Human | Breast | IDC | 8.30e-09 | 3.02e-01 | 0.1236 |
6144 | RPL21 | GSM4909293 | Human | Breast | IDC | 8.73e-40 | -2.58e-01 | 0.1581 |
6144 | RPL21 | GSM4909296 | Human | Breast | IDC | 5.06e-29 | 2.63e-01 | 0.1524 |
6144 | RPL21 | GSM4909297 | Human | Breast | IDC | 6.12e-103 | 4.35e-01 | 0.1517 |
6144 | RPL21 | GSM4909298 | Human | Breast | IDC | 2.94e-09 | 1.64e-01 | 0.1551 |
6144 | RPL21 | GSM4909299 | Human | Breast | IDC | 1.63e-13 | 1.81e-01 | 0.035 |
6144 | RPL21 | GSM4909301 | Human | Breast | IDC | 1.02e-44 | -3.65e-01 | 0.1577 |
6144 | RPL21 | GSM4909304 | Human | Breast | IDC | 2.92e-53 | -3.55e-01 | 0.1636 |
6144 | RPL21 | GSM4909305 | Human | Breast | IDC | 4.41e-06 | 1.28e-01 | 0.0436 |
6144 | RPL21 | GSM4909307 | Human | Breast | IDC | 8.26e-18 | -2.10e-01 | 0.1569 |
6144 | RPL21 | GSM4909308 | Human | Breast | IDC | 6.32e-23 | -2.22e-01 | 0.158 |
6144 | RPL21 | GSM4909311 | Human | Breast | IDC | 3.75e-12 | 7.52e-02 | 0.1534 |
6144 | RPL21 | GSM4909312 | Human | Breast | IDC | 1.81e-09 | 1.69e-01 | 0.1552 |
6144 | RPL21 | GSM4909315 | Human | Breast | IDC | 8.48e-08 | -1.65e-01 | 0.21 |
6144 | RPL21 | GSM4909319 | Human | Breast | IDC | 1.56e-24 | -4.19e-01 | 0.1563 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000218114 | Breast | IDC | cytoplasmic translation | 82/1434 | 148/18723 | 2.60e-52 | 1.48e-48 | 82 |
GO:000218124 | Breast | DCIS | cytoplasmic translation | 82/1390 | 148/18723 | 2.21e-53 | 1.25e-49 | 82 |
GO:000218110 | Cervix | CC | cytoplasmic translation | 96/2311 | 148/18723 | 4.87e-51 | 2.91e-47 | 96 |
GO:000218115 | Cervix | HSIL_HPV | cytoplasmic translation | 86/737 | 148/18723 | 3.97e-82 | 1.91e-78 | 86 |
GO:000218125 | Cervix | N_HPV | cytoplasmic translation | 42/534 | 148/18723 | 2.61e-30 | 1.19e-26 | 42 |
GO:0002181 | Colorectum | AD | cytoplasmic translation | 109/3918 | 148/18723 | 3.40e-43 | 2.13e-39 | 109 |
GO:00021811 | Colorectum | SER | cytoplasmic translation | 102/2897 | 148/18723 | 1.38e-48 | 8.49e-45 | 102 |
GO:00021812 | Colorectum | MSS | cytoplasmic translation | 108/3467 | 148/18723 | 1.78e-47 | 1.11e-43 | 108 |
GO:00021813 | Colorectum | MSI-H | cytoplasmic translation | 100/1319 | 148/18723 | 1.50e-79 | 8.31e-76 | 100 |
GO:00021814 | Colorectum | FAP | cytoplasmic translation | 76/2622 | 148/18723 | 3.31e-27 | 2.03e-23 | 76 |
GO:000218116 | Endometrium | AEH | cytoplasmic translation | 104/2100 | 148/18723 | 1.01e-64 | 6.07e-61 | 104 |
GO:000218117 | Endometrium | EEC | cytoplasmic translation | 104/2168 | 148/18723 | 2.53e-63 | 1.52e-59 | 104 |
GO:000218127 | Esophagus | HGIN | cytoplasmic translation | 108/2587 | 148/18723 | 1.70e-60 | 1.02e-56 | 108 |
GO:0002181111 | Esophagus | ESCC | cytoplasmic translation | 135/8552 | 148/18723 | 4.17e-32 | 2.65e-29 | 135 |
GO:00021817 | Liver | NAFLD | cytoplasmic translation | 93/1882 | 148/18723 | 1.44e-55 | 8.41e-52 | 93 |
GO:000218112 | Liver | Cirrhotic | cytoplasmic translation | 120/4634 | 148/18723 | 2.95e-47 | 1.85e-43 | 120 |
GO:000218122 | Liver | HCC | cytoplasmic translation | 132/7958 | 148/18723 | 9.09e-33 | 5.76e-30 | 132 |
GO:00021818 | Lung | IAC | cytoplasmic translation | 85/2061 | 148/18723 | 3.11e-43 | 1.85e-39 | 85 |
GO:000218113 | Lung | AIS | cytoplasmic translation | 85/1849 | 148/18723 | 5.48e-47 | 3.19e-43 | 85 |
GO:000218123 | Lung | AAH | cytoplasmic translation | 64/613 | 148/18723 | 1.74e-55 | 7.99e-52 | 64 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0301061 | Stomach | CAG | Ribosome | 61/368 | 167/8465 | 2.85e-41 | 8.23e-39 | 6.59e-39 | 61 |
hsa0517161 | Stomach | CAG | Coronavirus disease - COVID-19 | 63/368 | 232/8465 | 7.19e-34 | 1.04e-31 | 8.32e-32 | 63 |
hsa0301071 | Stomach | CAG | Ribosome | 61/368 | 167/8465 | 2.85e-41 | 8.23e-39 | 6.59e-39 | 61 |
hsa0517171 | Stomach | CAG | Coronavirus disease - COVID-19 | 63/368 | 232/8465 | 7.19e-34 | 1.04e-31 | 8.32e-32 | 63 |
hsa0301081 | Stomach | WIM | Ribosome | 49/284 | 167/8465 | 1.59e-33 | 4.44e-31 | 3.54e-31 | 49 |
hsa0517181 | Stomach | WIM | Coronavirus disease - COVID-19 | 53/284 | 232/8465 | 3.00e-30 | 4.20e-28 | 3.35e-28 | 53 |
hsa0301091 | Stomach | WIM | Ribosome | 49/284 | 167/8465 | 1.59e-33 | 4.44e-31 | 3.54e-31 | 49 |
hsa0517191 | Stomach | WIM | Coronavirus disease - COVID-19 | 53/284 | 232/8465 | 3.00e-30 | 4.20e-28 | 3.35e-28 | 53 |
hsa03010101 | Stomach | SIM | Ribosome | 62/465 | 167/8465 | 3.51e-36 | 1.07e-33 | 8.57e-34 | 62 |
hsa05171101 | Stomach | SIM | Coronavirus disease - COVID-19 | 65/465 | 232/8465 | 1.47e-29 | 2.23e-27 | 1.79e-27 | 65 |
hsa03010111 | Stomach | SIM | Ribosome | 62/465 | 167/8465 | 3.51e-36 | 1.07e-33 | 8.57e-34 | 62 |
hsa05171111 | Stomach | SIM | Coronavirus disease - COVID-19 | 65/465 | 232/8465 | 1.47e-29 | 2.23e-27 | 1.79e-27 | 65 |
Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RPL21 | SNV | Missense_Mutation | novel | c.278T>G | p.Ile93Ser | p.I93S | P46778 | protein_coding | deleterious(0.02) | benign(0.242) | TCGA-D8-A140-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin+cyclophosphamid | SD |
RPL21 | SNV | Missense_Mutation | c.45N>A | p.Phe15Leu | p.F15L | P46778 | protein_coding | deleterious(0.04) | possibly_damaging(0.539) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
RPL21 | SNV | Missense_Mutation | c.95N>A | p.Arg32Gln | p.R32Q | P46778 | protein_coding | tolerated(0.26) | benign(0.02) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD | |
RPL21 | SNV | Missense_Mutation | novel | c.107A>C | p.Lys36Thr | p.K36T | P46778 | protein_coding | deleterious(0.03) | possibly_damaging(0.673) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
RPL21 | SNV | Missense_Mutation | novel | c.222T>G | p.Ile74Met | p.I74M | P46778 | protein_coding | deleterious(0.01) | probably_damaging(0.938) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RPL21 | SNV | Missense_Mutation | c.148N>C | p.Lys50Gln | p.K50Q | P46778 | protein_coding | deleterious(0.02) | possibly_damaging(0.818) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
RPL21 | SNV | Missense_Mutation | c.388C>T | p.Arg130Cys | p.R130C | P46778 | protein_coding | tolerated(0.18) | benign(0.007) | TCGA-B5-A11Y-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
RPL21 | SNV | Missense_Mutation | novel | c.345N>C | p.Lys115Asn | p.K115N | P46778 | protein_coding | deleterious(0.04) | benign(0.061) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
RPL21 | SNV | Missense_Mutation | c.322N>T | p.Arg108Cys | p.R108C | P46778 | protein_coding | tolerated(0.16) | benign(0.001) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RPL21 | SNV | Missense_Mutation | c.431N>C | p.Asn144Thr | p.N144T | P46778 | protein_coding | tolerated(0.07) | benign(0.082) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |